MeiraGTx (MGTX) Competitors $7.32 -0.01 (-0.14%) Closing price 04:00 PM EasternExtended Trading$7.31 -0.01 (-0.14%) As of 04:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock MGTX vs. TARS, IDYA, OCUL, MLYS, IBRX, DNLI, IRON, BEAM, CNTA, and BLTEShould you be buying MeiraGTx stock or one of its competitors? The main competitors of MeiraGTx include Tarsus Pharmaceuticals (TARS), IDEAYA Biosciences (IDYA), Ocular Therapeutix (OCUL), Mineralys Therapeutics (MLYS), ImmunityBio (IBRX), Denali Therapeutics (DNLI), Disc Medicine (IRON), Beam Therapeutics (BEAM), Centessa Pharmaceuticals (CNTA), and Belite Bio (BLTE). These companies are all part of the "pharmaceutical products" industry. MeiraGTx vs. Its Competitors Tarsus Pharmaceuticals IDEAYA Biosciences Ocular Therapeutix Mineralys Therapeutics ImmunityBio Denali Therapeutics Disc Medicine Beam Therapeutics Centessa Pharmaceuticals Belite Bio MeiraGTx (NASDAQ:MGTX) and Tarsus Pharmaceuticals (NASDAQ:TARS) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, dividends, valuation, risk, profitability, media sentiment, institutional ownership and earnings. Which has better valuation & earnings, MGTX or TARS? Tarsus Pharmaceuticals has higher revenue and earnings than MeiraGTx. Tarsus Pharmaceuticals is trading at a lower price-to-earnings ratio than MeiraGTx, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMeiraGTx$37.92M15.53-$147.79M-$2.04-3.59Tarsus Pharmaceuticals$295.52M7.23-$115.55M-$2.33-21.72 Do analysts prefer MGTX or TARS? MeiraGTx currently has a consensus target price of $24.00, indicating a potential upside of 227.87%. Tarsus Pharmaceuticals has a consensus target price of $66.67, indicating a potential upside of 31.75%. Given MeiraGTx's stronger consensus rating and higher possible upside, equities analysts clearly believe MeiraGTx is more favorable than Tarsus Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score MeiraGTx 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00Tarsus Pharmaceuticals 0 Sell rating(s) 2 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.71 Does the media refer more to MGTX or TARS? In the previous week, Tarsus Pharmaceuticals had 5 more articles in the media than MeiraGTx. MarketBeat recorded 7 mentions for Tarsus Pharmaceuticals and 2 mentions for MeiraGTx. MeiraGTx's average media sentiment score of 1.18 beat Tarsus Pharmaceuticals' score of 0.57 indicating that MeiraGTx is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MeiraGTx 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Tarsus Pharmaceuticals 2 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has more volatility and risk, MGTX or TARS? MeiraGTx has a beta of 1.29, suggesting that its stock price is 29% more volatile than the S&P 500. Comparatively, Tarsus Pharmaceuticals has a beta of 0.81, suggesting that its stock price is 19% less volatile than the S&P 500. Do institutionals & insiders have more ownership in MGTX or TARS? 67.5% of MeiraGTx shares are owned by institutional investors. Comparatively, 90.0% of Tarsus Pharmaceuticals shares are owned by institutional investors. 7.5% of MeiraGTx shares are owned by insiders. Comparatively, 9.0% of Tarsus Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. Is MGTX or TARS more profitable? Tarsus Pharmaceuticals has a net margin of -31.13% compared to MeiraGTx's net margin of -415.39%. Tarsus Pharmaceuticals' return on equity of -32.36% beat MeiraGTx's return on equity.Company Net Margins Return on Equity Return on Assets MeiraGTx-415.39% -314.44% -63.28% Tarsus Pharmaceuticals -31.13%-32.36%-21.04% SummaryTarsus Pharmaceuticals beats MeiraGTx on 9 of the 16 factors compared between the two stocks. Get MeiraGTx News Delivered to You Automatically Sign up to receive the latest news and ratings for MGTX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding MGTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MGTX vs. The Competition Export to ExcelMetricMeiraGTxMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$588.87M$3.09B$5.70B$10.27BDividend YieldN/A2.32%5.72%4.60%P/E Ratio-3.5921.3075.8626.51Price / Sales15.53380.87491.12165.50Price / CashN/A44.4425.8129.89Price / Book8.419.6112.846.32Net Income-$147.79M-$53.28M$3.28B$270.51M7 Day Performance-4.31%0.32%0.22%2.15%1 Month Performance-10.40%4.59%4.61%6.35%1 Year Performance74.29%9.24%68.33%25.49% MeiraGTx Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MGTXMeiraGTx4.1417 of 5 stars$7.32-0.1%$24.00+227.9%+72.5%$588.87M$37.92M-3.59300News CoveragePositive NewsTARSTarsus Pharmaceuticals2.5028 of 5 stars$56.89-1.3%$66.67+17.2%+49.1%$2.43B$182.95M-24.4250Positive NewsIDYAIDEAYA Biosciences3.9601 of 5 stars$23.39-13.9%$45.77+95.7%-34.5%$2.38B$7M-6.1780High Trading VolumeOCULOcular Therapeutix3.8887 of 5 stars$12.71-6.5%$17.20+35.3%+39.3%$2.37B$63.72M-9.93230News CoveragePositive NewsAnalyst ForecastMLYSMineralys Therapeutics2.8301 of 5 stars$35.93+3.2%$36.60+1.9%+207.9%$2.31BN/A-10.0928Positive NewsGap DownIBRXImmunityBio2.5102 of 5 stars$2.41+0.4%$10.75+346.1%-23.5%$2.27B$14.74M-5.02590DNLIDenali Therapeutics4.2906 of 5 stars$15.50+0.5%$33.62+116.9%-57.2%$2.26B$330.53M-5.54430Positive NewsIRONDisc Medicine3.227 of 5 stars$61.91+1.9%$98.30+58.8%+25.3%$2.11BN/A-13.8530Positive NewsHigh Trading VolumeBEAMBeam Therapeutics3.0305 of 5 stars$19.94-4.5%$48.45+143.0%-19.1%$2.11B$63.52M-4.43510Analyst DowngradeCNTACentessa Pharmaceuticals3.1276 of 5 stars$18.03+14.6%$31.45+74.5%+29.6%$2.11B$6.85M-10.07200Insider TradeHigh Trading VolumeBLTEBelite Bio2.5151 of 5 stars$67.51+2.7%$96.67+43.2%+36.8%$2.09BN/A-43.5510News CoverageAnalyst Forecast Related Companies and Tools Related Companies TARS Competitors IDYA Competitors OCUL Competitors MLYS Competitors IBRX Competitors DNLI Competitors IRON Competitors BEAM Competitors CNTA Competitors BLTE Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:MGTX) was last updated on 9/16/2025 by MarketBeat.com Staff From Our PartnersFanatics Hit $31B-Is This Nasdaq Next?Fanatics built an empire by owning the fan experience-scaling to a $31B valuation. But the next wave isn't abo...i2i Marketing Group, LLC | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredForget NVDA. Put $1,000 into this stock nowA massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | SponsoredWhy More Investors Are Using Family Trusts to Protect Their WealthFor many investors, a family trust can be an essential tool for protecting assets, avoiding probate, and ensur...SmartAsset | SponsoredNvidia Times 1,000,000Nvidia’s latest AI chip is a $25,000 powerhouse — with 80 billion transistors and the ability to perform 60 tr...Paradigm Press | SponsoredOpenAI’s new $300 billion dealOpenAI just signed a $300 billion cloud deal with Oracle to secure the computing power needed for its next Cha...Porter & Company | SponsoredCollege grad makes $64,000 a monthA Wall Street legend just helped train our own proprietary AI system in the stock market (a project that took ...Stansberry Research | SponsoredCrypto Gets Official Government Backing—Here's the WinnerTrump Just Signed the GENIUS Act—One Coin is About to Explode We're at the BEGINNING of smart money really ...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding MeiraGTx Holdings PLC Please log in to your account or sign up in order to add this asset to your watchlist. Share MeiraGTx With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
